Determination of the launch date and related background of fosdenopterin

Fosdenoprin (trade name: Nulibry®) obtained the U.S. Food and Drug Administration approval on February 16, 2021. Approved by the Food and Drug Administration (FDA), it became the first drug to treat A molybdenum cofactor deficiency (MoCD-A).

MoCD-A is a rare autosomal recessive disease caused by mutations in the MOCS1 gene, leading to an impairment in the synthesis of molybdenum cofactor (MoCo). MoCois an essential cofactor for a variety of molybdenum-dependent enzymes (such as sulfite oxidase, xanthine dehydrogenase/oxidase, aldehyde oxidase). Its deficiency can lead to the accumulation of neurotoxic metabolites (such as sulfite), causing brain damage, epileptic seizures, and early death. The disease usually develops in the neonatal period or early infancy and has a high mortality rate in untreated patients.

Fosdenopterin, developed byBridgeBio Pharma and its subsidiariesOrigin Biosciences, is the hydrobromide dihydrate of cyclic pyranopterin monophosphate (cPMP). The drug improves the activity of molybdenum-dependent enzymes by providing exogenous cPMP to replace the missing substrate in the patient's body and restore the synthesis of molybdenum cofactors.

Clinical trials of Fosdenoprin (such asNCT02637234) showed a three-year survival rate of 84% for patients who received treatment, compared with only 55% for those who did not receive treatment. The drug's safety and effectiveness have been recognized by the FDA and it has been granted orphan drug status and priority review status.

Fosdenopterin is the first approved drug targetingMoCD-A, filling the treatment gap for this disease. Its launch provides hope for MoCD-A patients and significantly improves prognosis.

The drug has been approved in the United States, Canada and Australia, providing globalMoCD-A provides new treatment options for patients.

The launch of Fosdenoprin marks a major breakthrough in the treatment field of MoCD-A, bringing new hope to patients and promoting the development of rare disease drugs.

Reference materials:https://nulibry.com/